Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ivenix Inc.
Fresenius Brings In Transparency Change For Kabi Unit
Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.
Jones And Luber Partner Up Again At Atlas Genetics
Marc Jones is taking on the dual role of chief operating officer and chief financial officer at UK point-of-care diagnostics firm Atlas Genetics.
Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Infusion-Pump Maker Ivenix Closes Initial Tranche Of $50m Financing
Ivenix Inc. said it has closed on the first tranche of $50m in equity financing, which will put the Amesbury, Massachusetts-based infusion-pump startup on track to pursue FDA approval for its Ivenix Infusion System.
- Digital Health
- Infusion Therapy Equipment and Supplies
- Other Names / Subsidiaries
- Fluidnet Corporation
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.